About Malecare

This author has not yet filled in any details.
So far Malecare has created 608 blog entries.

Prostate Cancer drugs cost more in the USA than in other countries.

The cost of Enzalutamide (Xtandi) in the United States is being challenged by Knowledge Ecology International (KEI), a public interest advocacy group.  The average US wholesale price of Xtandi in 2015 was $88 per capsule.   That can add up to $129,000 annual cost per man. There are significant issues related to high costs of treatment. [...]

Caution – The FDA Has Limited The Usage of Nizoral (ketoconazole)

Nizoral (ketoconazole, keto) is an older drug that has been used as a part of hormone therapy (ADT) for many years.  Keto, which is an inexpensive anti-fungal drug had been used for many years as an inhibitor of adrenal androgen synthesis as is abiriterone (Zytiga). Ztiga has been shown to be more effective, however, it [...]

The Cancer Moon Shot – Vice President Biden Speaks to the AACR

I recently returned home from the American Association of Cancer Researchers (AACR) annual meeting held in New Orleans, La. The meeting was, as usual fantastic, but this years conclusion was by far the best I have experienced. The meeting’s closing session was reserved for remarks about the cancer "moonshot" initiative from Vice President Joe Biden. [...]

Radioligand Therapy With 177Lu-PSMA-617 – A Novel Therapeutic Possibility on the Horizon in Men With Metastatic Castration Resistant Prostate Cancer.

We are seeing more and more novel therapies being developed to treat castrate resistant metastatic prostate cancer (mCRPC). One such therapy involves theranostic (individualized therapies for various diseases, and to combine diagnostic and therapeutic capabilities into a single agent) concepts using radiolabeled ligands of the prostate-specific membrane antigen (PSMA). In a recent study, designed to [...]

Radiotherapy Might Not Extend Survival In Men With Prostate Cancer Who Are Under 70 Years Old

Increasingly, we are seeing younger men diagnosed with prostate cancer and with bone metastases. One of the more common therapies, radiotherapy is recognized for its effect on local control of bone metastases, but whether it could prolong overall survival, the gold standard is still controversial. Researchers retrospectively evaluated 113 men with prostate cancer and bone [...]

Go to Top